Reuters have reported that an experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than older therapies.
The J&J drug, canagliflozin, also showed considerably greater weight loss than both of the other drugs and far fewer incidents of hypoglycemia, or potentially dangerous drops in blood sugar levels. Canagliflozin, belongs to a new class of diabetes treatments called SGLT2 inhibitors that work by blocking reabsorption of glucose by the kidney and increases glucose excretion in the urine to lower blood sugar.
This information came from date collected in two 52-week studies. The date was presented on Saturday at the American Diabetes Association (ADA) meeting in Philadelphia, are part of a massive approval application J&J submitted to the U.S. Food and Drug Administration last week that comprised nine separate Phase III trials involving more than 10,000 patients
If approved it would be J&J’s first diabetes medicine.
Are you looking for a new position in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online now.
Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates